Condition: NSCLC, Stage I · Sponsor: Greg Durm, MD
A randomized trial of adjuvant Pembrolizumab following surgical resection versus observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm. Patients will be randomized (1:1) 4-12 weeks following surgery to either: * Arm A: Pembrolizumab 400 mg every 6 weeks × 9 cycles * Arm B: Observation Stratification factors will include: PD-L1 TPS (\<50% vs. ≥50%), and tumor size (1-2 cm vs. \>2-4 cm)
This description comes directly from the study's public registry record.
Greg Durm, MD · 317-944-3940 · gdurm@iu.edu
Allison Lipps · 317-634-5842 · alipps@hoosiercancer.org
Always discuss trial participation with your own doctor first.
| Moffit Cancer Center | Tampa, Florida, United States | Recruiting |
| University of Illinois Cancer Center | Chicago, Illinois, United States | Recruiting |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis, Indiana, United States | Recruiting |
| University of Iowa Hospitals and Clinics | Iowa City, Iowa, United States | Recruiting |
| University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| University of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | Recruiting |
| Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Recruiting |
| Providence Health & Services - Oregon | Portland, Oregon, United States | Recruiting |
| Penn State Cancer Institute | Hershey, Pennsylvania, United States | Recruiting |
| University of Virginia Health System | Charlottesville, Virginia, United States | Recruiting |
| Virginia Commonwealth University | Richmond, Virginia, United States | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04317534